

## ORIGINAL ARTICLE

# The genus *Actinoallomurus* and some of its metabolites

Roberta Pozzi<sup>1,2</sup>, Matteo Simone<sup>2,3</sup>, Carlo Mazzetti<sup>2,3</sup>, Sonia Maffioli<sup>2</sup>, Paolo Monciardini<sup>1,4</sup>, Linda Cavaletti<sup>4</sup>, Ruggiero Bamonte<sup>4</sup>, Margherita Sosio<sup>1,2</sup> and Stefano Donadio<sup>1,2</sup>

In the search for novel antibiotics, natural products continue to represent a valid source of bioactive molecules. During a program aimed at identifying previously unreported taxa of actinomycetes as potential source of novel compounds, we isolated hundreds of different representatives of a new group, initially designated as 'Alpha' and independently described as *Actinoallomurus*. We report on a PCR-specific method for the detection of this taxon, on appropriate growth conditions and on a pilot-screening program on 78 strains. The strains produce antibacterial or antifungal compounds at a relatively high frequency. Four strains were characterized in further detail: one produced the aromatic polyketide benanomycin B and its dextylosyl derivative; a second strain produced *N*-butylbenzenesulfonamide; a third strain was an efficient converter of soymeal isoflavonoids from soymeal constituents; and a fourth strain produced several coumermycin-related aminocoumarins, with coumermycin A2 as the major peak, and with some new congeners as minor components of the complex. These data suggest that *Actinoallomurus* strains possess several pathways for secondary metabolism and represent an attractive source in the search for novel antibiotics.

*The Journal of Antibiotics* (2011) 64, 133–139; doi:10.1038/ja.2010.149; published online 1 December 2010

**Keywords:** actinomycetes; screening; secondary metabolites

## INTRODUCTION

New antibiotics are urgently needed because of the increasing spread of resistant pathogens and the evolution of new diseases. As microbial genomes, synthetic libraries and high throughput screening have so far failed to produce a significant number of developmental candidates in the antibacterial field, it is generally acknowledged that nature will continue to be a significant source of novel bioactive compounds,<sup>1</sup> as confirmed by a recent survey of antibiotics under clinical development.<sup>2</sup> However, in a background of several thousands of known microbial metabolites, it is necessary to introduce new strategies for accessing microbial strains to increase the probability of finding novel compounds. Chemical screening<sup>3</sup> and, more recently, genome mining<sup>4</sup> are alternatives to the traditional bioassay-guided screening. In the latter case, the probability of finding new compounds may be increased by the use of novel assays, of novel microorganisms or by the mere size of the library to be screened.<sup>5</sup> In any case, dedicated efforts are providing novel metabolites.<sup>6</sup>

In the past years, our attention has been drawn to previously uncultured actinomycetes, under the assumption that strains belonging to novel taxa, which are however phylogenetically related to prolific producers of secondary metabolites, have a high chance of possessing diverse pathways in secondary metabolism and of affording novel compounds.<sup>7</sup> A 16S-guided isolation program led to the

identification of several new taxa,<sup>7</sup> three of which have been subsequently formally described.<sup>8–10</sup> During that program we were also able to isolate hundreds of different strains provisionally designated as 'Alpha', whose phylogenetic position suggested a new taxon within the *Actinobacteria*.<sup>7</sup> Independently, phylogenetically related strains have been assigned to the recently described genus *Actinoallomurus*.<sup>11</sup>

We present here a characterization of 'Alpha' strains present in our collections, in terms of their potential to produce secondary metabolites. The results from a small pilot study suggest that the genus *Actinoallomurus* has the potential to produce metabolites arising from different biosynthetic pathways.

## RESULTS

In the course of isolation programs, aimed at identifying actinomycetes belonging to new taxa,<sup>7</sup> we isolated from soil samples several actinomycete strains, with branching aerial hyphae that, as observed by light microscopy on agar plates, differentiated into single spore chains along the aerial mycelium, reminiscent of some *Actinomadura* strains. Most of the strains were able to grow in the 30–37 °C temperature range at an optimal pH of 5.5. Phylogenetic analysis of selected strains indicated they belong to the recently described genus *Actinoallomurus* within the *Thermomonosporaceae*.<sup>11</sup> Furthermore, on 16S rRNA analysis, we were able to subdivide 115 strains in 32 'Alp'

<sup>1</sup>KtedoGen Srl, Milano, Italy; <sup>2</sup>NAICONS Srl, Milano, Italy; <sup>3</sup>ITB-CNR, Segrate, Italy and <sup>4</sup>Vicuron Pharmaceuticals, Gerenzano, Italy

Correspondence: Dr S Donadio, NAICONS Srl, Via Fantoli 16/15, 20138 Milano, Italy.

E-mail: sdonadio@naicons.com

Dedicated to late Dr C Richard Hutchinson for his exceptional contributions to natural product biosynthesis, engineering and drug discovery.

Received 3 October 2010; revised 27 October 2010; accepted 1 November 2010; published online 1 December 2010

phylotypes (Figure 1), indicating a substantial diversity within this genus.


For the rapid identification of novel isolates, we developed an *Actinoallomurus*-specific PCR method (see Methods). When we applied this method to soil samples, about 25% of soil DNA preparations yielded a band of the expected size,<sup>7</sup> suggesting that *Actinoallomurus* strains may be quite cosmopolitan. Consistently, strains with an alpha-type morphology were isolated from many different soils, and the PCR method proved an effective tool for rapidly assigning most of them to *Actinoallomurus*.

The *Thermomonosporaceae* family currently comprises five genera but, to our knowledge, only strains belonging to the genus *Actinomadura* have been reported to produce secondary metabolites. To evaluate the ability of *Actinoallomurus* strains to produce bioactive compounds, we identified suitable growth conditions (see Methods). Examples of HPLC profiles are reported in Figure 2: different strains yielded different profiles, suggesting production of different secondary metabolites. Next, a pilot-screening program was carried out on


78 different strains belonging to 26 different phylotypes. About 30% of the tested strains showed at least an antimicrobial activity in our conditions (Table 1). These results prompted us to further investigate these strains and identify the bioactive metabolites produced. Here, we report the metabolites identified from four strains belonging to different phylotypes. The data are summarized in Table 2.

### Strain K15

Strain K15 produced an antifungal activity and a diffusible red pigment. In all tested media, it showed good growth, and production of the red pigment and of the antifungal activity, both of which could be efficiently recovered from the mycelium by MeOH extraction. HPLC fractionation of the MeOH extract, followed by LC-MS of the active fractions, led to the identification of two peaks eluting at 14.5 and 16.0 mins, containing the major antifungal activity (Figure 3). These peaks exhibited UV-VIS maxima at 500 nm and showed [MH<sup>+</sup>] of 827 and 696 *m/z*, respectively. Searches in the ABL database identified the antifungal compounds benanomycin B and its dexylosyl



**Figure 1** The 'Alp' phylotypes within *Actinoallomurus*. Phylogenetic tree of one representative from each Alp phylotype, nine *Actinoallomurus* species and selected representatives of other *Thermomonosporaceae* genera.



**Figure 2** HPLC profiles of selected 'Alpha' strains. Strains were grown in AF5.5 for 9 days and MeOH extracts from entire culture were analyzed as described under Methods, with detector set at 230 nm. Strains were as follows: a, K15; b, K79; c, K247; d, K275; and e, K277.

**Table 1** Summary of screening results

Test strain	Strains	Positives	Confirmed as Alp <sup>a</sup>
<i>S. aureus</i>	78	22 <sup>b</sup>	21 <sup>b</sup>
<i>E. coli</i>	78	6 <sup>b</sup>	6 <sup>b</sup>
<i>C. albicans</i>	78	4	3

Abbreviation: Alp, Alpha.

<sup>a</sup>By 16S rRNA gene sequencing and/or by the specific PCR method.

<sup>b</sup>Five strains showed activity on both *S. aureus* and *E. coli*.

derivative, respectively,<sup>12</sup> as likely candidates for the metabolites produced by strain K15. This was confirmed on a larger preparation of the 14.5-min fraction from the NMR signals at 6.9–7.27 and 3.2–4.75 p.p.m., expected from aromatic and sugar protons, respectively, and by observing MS/MS fragmentations of  $m/z$  values of 695, 550 and 461, expected from the loss of the first and the second sugar and the alanine residue, respectively (data not shown).

### Strain K216

Strain K216, selected for its anti-*Streptomyces aureus* activity, produced on agar plates, a cell-associated violet pigment turning dark green with age. This activity could be recovered from both the mycelium and the cleared broth. Ethyl acetate extraction of the cleared fermentation broth, HPLC fractionation and LC-MS analyses led to the identification of one peak eluting at 15.7 min containing the major antibiotic activity (Figure 4). One of the molecules present in this fraction showed a  $[M+H]^+$  of 214  $m/z$ . Search in the ABL database suggested *N*-butylbenzenesulphonamide<sup>13</sup> as the likely compound. NMR analysis confirmed this structure by comparison with the literature data.

### Strain K241

K241 sporulates well on agar plates, in which it produces an agar-diffusible black pigment. The strain produced an antistaphylococcal activity, which was observed in the mycelium from INA5-15 cultures, despite a relatively poor growth in this medium. LC-MS analysis identified  $[M+H]^+$  peaks with  $m/z$  values of 271, 285 and 255, which matched the isoflavonoids genistein, 7-*O*-methyl-genistein and daidzein, respectively. These compounds, which show antibacterial activity as well as different pharmacological effects in animal cells,<sup>14</sup> have been reported before from actinomycetes,<sup>15</sup> although it has been suggested that these metabolites derive from microbial hydrolysis of glycosidic plant isoflavonoids present in the culture medium rather than from

**Table 2** Summary of analyzed strains

Alp strain	Phylotype	Original bioactivity	Identified metabolite(s)
K15	Alp13	<i>C. albicans</i>	Benanomicin B
K216	Alp25	<i>S. aureus</i>	<i>N</i> -Butylbenzenesulphonamide
K241	Alp16	<i>S. aureus</i>	Genistein and related compounds
K275	Alp18	<i>S. aureus</i>	Coumermycins

Abbreviation: Alp, Alpha.

*de novo* biosynthesis.<sup>16</sup> Consistently, HPLC analyses of organic extracts from strain K241 grown in INA5 medium containing 5 g l<sup>-1</sup> instead of 15 g l<sup>-1</sup> of soybean flour showed a corresponding decrease in the height of the genistein, 7-*O*-methylgenistein and daidzein peaks, which were absent altogether when soybean flour was omitted from INA5 or in a soybean flour-free medium such as RARE3 medium (Figure 5). These data suggest that strain K241 produces one or more enzymes able to deglycosylate plant isoflavonoids. Interestingly, irrespective of the presence of isoflavonoids, methanolic extracts still retained an activity against *S. aureus*, which still awaits identification.


### Strain K275

Colonies of strain K275 progressed from ochre to violet on agar plates. From a mycelium methanolic extract, the HPLC fractions, containing antistaphylococcal activity, matched in their UV and MS properties (Figure 6) with many congeners of the coumermycin complex.<sup>17</sup> NMR analysis of the most active fraction confirmed the presence of coumermycin A2 ( $m/z$  1082  $[M+H]^+$ ), whereas we inferred the presence of coumermycins D1, C and D ( $m/z$  values of 1096, 989 and 908  $[M+H]^+$ , respectively) by MS and MS/MS fragmentation. As minor components of the complex, we also identified potentially new coumermycin congeners showing  $m/z$  values of 1068 and 975  $[M+H]^+$ , with fragmentation patterns similar to coumermycin A2 and C, respectively. The small amounts of these congeners, amid large amounts of coumermycin A2, D1, C and D, prevented us from carrying out their structural characterization.


## DISCUSSION

Strains belonging to the genus *Actinoallomurus* seem to be present in different environments, as indicated by our isolation efforts and by screening soil DNA with our PCR method, as well as by their retrieval from different sources, including soils, plants and dung, by other groups.<sup>11,18–20</sup> Furthermore, our limited phylogenetic analysis indicates a discrete level of genotypic diversity. Thus, this genus appears to fulfill one requisite for being a valid source of bioactive compounds: the possibility to access a significant number of strains with a reasonable degree of diversity. Here, we have also started to address the bioactive metabolites produced by *Actinoallomurus* strains.

Despite the use of a limited number of culturing conditions, our results indicate that about 30% of the screened strains produce an antimicrobial activity against three test strains, a fraction that favorably compares with other, well-established genera of filamentous actinomycetes. From three different *Actinoallomurus* strains, we identified three unrelated compounds belonging to different chemical classes: benanomicin, coumermycin and *N*-butylbenzenesulphonamide. Benanomicin- and coumermycin-related compounds have been reported as the products of *Actinomadura* or *Streptomyces* strains. *N*-butylbenzenesulphonamide, an antifungal compound active against fungal plant pathogens, has been reported from a greenhouse-associated *Pseudomonas* strain<sup>13</sup> and, very recently, from a terrestrial



**Figure 3** Identification of active metabolites from strain K15. (a) HPLC profile of methanolic extract from mycelium, with analyzed peaks labeled as (I) and (II). (b) UV-VIS and MS spectra of (I).




**Figure 4** Identification of active metabolites from strain K216. (a) HPLC profile of ethyl acetate extract from cleared broth. (b) UV-VIS and MS spectra of (I).

*Streptomyces* sp.<sup>21</sup> In addition, the *Actinoallomurus* K241 strain appears to be an effective producer of isoflavonoids by biotransformation of soymeal constituents.


To our knowledge, the biosynthesis of *N*-butylbenzenesulphonamide has not been investigated. For the other compounds identified in this study, the benanomicin family of compounds requires the participation of a type II polyketide synthase, followed by glycosylations and other post-polyketide modifications.<sup>22</sup> Formation of coumermycin requires the tyrosine- and proline-derived aminocoumarin and 5-methyl-pyrrole-2-carboxyl moieties, respectively, as well as a

deoxysugar.<sup>23</sup> Furthermore, we previously reported the presence of type I polyketide synthase and nonribosomal peptide synthetase genes in *Actinoallomurus* strains,<sup>7</sup> a property commonly found in many *Actinobacteria* genera,<sup>24</sup> including recently described lineages.<sup>25</sup> Thus, at least some of the major pathways leading to bioactive compounds in filamentous actinomycetes are present in *Actinoallomurus*. These results would need to be complemented by analysis of selected genomes.

Although only four strains have been analyzed in this work, with just some new congeners from the coumermycin family identified, we



**Figure 5** Metabolites produced by strain K241. (a) HPLC profiles of methanolic extracts of cleared broths from strain K241 grown in (bottom to top): RARE3, INA5-0, INA5-5 and INA5-15. Top trace is starting INA5-15. Analyzed peaks are labeled as (I), (II) and (III). (b) UV-VIS and MS spectra of (I).



**Figure 6** Identification of active metabolites from strain K275. (a) HPLC profile of methanolic extract from mycelium, with analyzed peaks labeled as (I) and (II). (b) UV-VIS and MS spectra of (I).

believe that *Actinoallomurus* represents a promising source of novel bioactive metabolites. In this respect, the availability of ~1200 isolates in our strain collections represents an untapped resource worth exploring.

## METHODS

### Bacterial strains and growth conditions

The 'Alpha' strains used in this work were derived from the KtedoGen strain collection. In some cases, their affiliation with the genus *Actinoallomurus* was

confirmed by phylotyping. They were maintained on S15.5 plates (oatmeal 60 g l<sup>-1</sup>, agar 15 g l<sup>-1</sup>, adjusted to pH 5.5 with HCl). For liquid cultures, a loopful of mycelium was scraped from an agar plate, inoculated into 15 ml of AF5.5 (see ref. 5) in a 100-ml baffled flask. For a larger scale, a 10% inoculum from a 6-day AF5.5 culture was inoculated into 100–1000 ml of medium. Additional media used were M8 (see ref. 5), INA5-15 (see ref. 5), V6 (see ref. 26) and RARE3 (see ref. 27). INA5-5 and INA5-0 consist of INA5-15 containing 5 and 0 g l<sup>-1</sup> soybean flour, respectively. For all media, the pH was



adjusted to 5.5 with HCl before sterilization. All liquid cultures were incubated for 7–10 days at 37 °C on a rotary shaker at 200 r.p.m.

### PCR-selective method

Genomic DNA was extracted with the GenElute Bacterial Genomic DNA kit (Sigma-Aldrich, Munich, Germany) or by colony picking as described.<sup>28</sup> PCR amplification, sequence and phylogenetic analyses were performed as described.<sup>29</sup> Strains were assigned to the same phylotype if they shared >99.5% identity over 1400 bp of the 16S rRNA gene.

PCR primers for the specific amplification of the *Actinoallomurus* 16S rRNA gene were designed following a previously described procedure.<sup>29</sup> Briefly, aligned sequences obtained from *Actinoallomurus* strains were compared with the consensus sequences obtained for other genera and families of the *Actinomycetales*, and conserved regions within the *Actinoallomurus* sequences were probed against the RDP database (<http://rdp.cme.msu.edu/>) to discard aspecific primers. The specificity of selected primer pairs was then evaluated on genomic DNAs extracted from different actinomycete genera. This procedure led to selection of primers 5'-CGTGAGTAACCTGCCCYRG-3' and 5'-CKTWMGCTTCGTCGGTGG-3'. Reactions were performed in a final volume of 50 µl, containing 50 mM KCl, 10 mM Tris-HCl, pH 8.3 (20 °C), 500 nM of each primer, 0.2 mM of each dNTP, 1.5 mM MgCl<sub>2</sub>, 2 U of RedTaq DNA polymerase (Sigma-Aldrich) and 3 µl of 10× Denhardt's reagent (2 g Ficoll 400, 2 g polyvinylpyrrolidone, 2 g bovine serum albumin). Amplifications consisted of 30 cycles, each comprised of 30 s at 94 °C, 30 s at 60 °C and 60 s at 72 °C. The program was initiated by 5 min at 95 °C and terminated with 10 min at 72 °C. The method was validated on a panel of genomic DNAs from *Actinoallomurus* strains and from negative controls (strains belonging to other *Actinobacteria* genera, including other *Thermomonosporaceae*). The expected 0.34 kbp fragment was obtained only from strains whose 16S rRNA gene sequence clearly clustered within *Actinoallomurus*.

### Antimicrobial assays

MeOH extracts of cultures were prepared as follows: 450 µl of broth culture was shaken at 1400 r.p.m. with 900 µl MeOH for 1 h at 40 °C. The mycelium was removed by centrifugation, the supernatant was evaporated under vacuum and resuspended in 100 µl of 10% DMSO. Occasionally, bioactivity was determined employing agar plugs cut from 7 to 10-day-old S15.5 plates. Agar plugs or 20 µl of the resuspended MeOH extract were deposited on 4-mm thick Müller Hinton Agar (Difco Laboratories, Detroit, MI, USA) plates, inoculated with 10<sup>5</sup> c.f.u. ml<sup>-1</sup> *S. aureus* ATCC 6538P, with 10<sup>5</sup> c.f.u. ml<sup>-1</sup> *Escherichia coli* K2526 (a *AtolC* derivative of MG1655), or with 10<sup>4</sup> c.f.u. ml<sup>-1</sup> *Candida albicans* SKF 2270 (in the latter case, the medium was supplemented with 2% glucose). Plates were incubated overnight at 37 °C before scoring the inhibition halos.

### Metabolite identification

Metabolites were extracted from liquid cultures by adding two volumes of MeOH to the entire culture and thoroughly mixing for 1 h at 50 °C. After centrifugation, the liquid phase was dried under vacuum and dissolved in 0.5 ml 10% DMSO per ml of original culture. An aliquot was fractionated on a Shimadzu Series 10 system (Kyoto, Japan), equipped with a reversed-phase column, Lichrosorb RP-18, 5 µm, 4×250 mm (Merck, Darmstadt, Germany) and a diode array detector, using a linear gradient of 0.05 M ammonium formate-acetonitrile (from 5 to 90% of organic phase in 30 min) at a flow rate of 1 ml min<sup>-1</sup>. Fractions (1 ml) from the HPLC column were collected, dried and resuspended in 100 µl 10% DMSO, and 20 µl was tested for bioactivity.

Preparative HPLC employed a Shimadzu Series 10 spectrophotometer, Merck Lichrosphere C18 4.6×100-mm column, diode array detector (190–800 nm), using a linear gradient of eluents A (0.1% TFA in 0.05 M HCOONH<sub>4</sub>) and B (acetonitrile) from 5 to 90% B in 30 min at a flow rate of 1 ml min<sup>-1</sup>. Reversed-phase medium pressure liquid chromatography was performed on a Combiflash ISCO (Teledyne ISCO, Lincoln, NE, USA) RP18 12 g column, with a 20-min linear gradient from 5 to 90% eluent B in 20 min at 18 ml min<sup>-1</sup>. ESI-MS data were recorded on a MS Bruker (Karlsruhe, Germany) Ion Trap ESQUIRE 3000 Plus spectrometer, LC Agilent 1100 DAD. <sup>1</sup>H and <sup>13</sup>C 1- and

2D-NMR spectra (COSY, TOCSY, NOESY, HSQC, HMBC) were measured in DMSO-d<sub>6</sub>, CDCl<sub>3</sub> or MeOD-d<sub>4</sub>, on Bruker 400 or 600 MHz instruments.

The UV properties and mass data of the molecules present in the active fractions were queried against the ABL database, which contains data on approximately 29 000 microbial metabolites published up to 2006. An earlier version of the database was previously described.<sup>30</sup>

### ACKNOWLEDGEMENTS

Work at KtedoGen was partially supported by grants from Italian Ministry of Research and from Regione Lombardia. M Simone and C Mazzetti were directly supported from a fellowship from Regione Lombardia.

- Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. *Science* **325**, 1089–1093 (2009).
- Donadio, S., Maffioli, S., Monciardini, P., Sosio, M. & Jabes, D. Antibiotic discovery in the twenty-first century: current trends and future perspectives. *J. Antibiot.* **63**, 423–4530 (2010).
- Maier, A. et al. Biomolecular-chemical screening: a novel screening approach for the discovery of biologically active secondary metabolites. I. Screening strategy and validation. *J. Antibiot.* **52**, 945–951 (1999).
- Corre, C. & Challis, G. L. New natural product biosynthetic chemistry discovered by genome mining. *Nat. Prod. Rep.* **26**, 977–986 (2009).
- Donadio, S., Monciardini, P. & Sosio, M. Approaches to discovering novel antibacterial and antifungal agents. *Meth. Enzymol.* **438**, 3–28 (2009).
- Singh, S. B. & Young, K. New antibiotic structures from fermentations. *Expert Opin. Ther. Pat.* **20**, 1359–1371 (2010).
- Donadio, S. et al. Sources of polyketides and non-ribosomal peptides. *Ernst Schering Res Found Workshop* **51**, 19–41 (2005).
- Busti, E. et al. *Catenulispora acidiphila* gen. nov., sp. nov., a novel mycelium-forming actinomycete and proposal of *Catenulisporaceae* fam. nov.. *Int. J. Syst. Evol. Microbiol.* **56**, 1741–1756 (2006).
- Cavaletti, L. et al. *Actinospica acidiphila* gen. nov., sp. nov., and *Actinospica robiniae* gen. nov., sp. nov.; proposal for *Actinospicaceae* fam. nov. and *Catenulisporinae* subordo nov. in the order *Actinomycetales*. *Int. J. Syst. Evol. Microbiol.* **56**, 1747–1753 (2006).
- Monciardini, P. et al. Two novel members of the family *Micromonosporaceae*, *Rugosimonospora acidiphila* gen. nov. sp. nov. and *Rugosimonospora africana* sp. nov. *Int. J. Syst. Evol. Microbiol.* **59**, 2752–2758 (2009).
- Tamura, T., Ishida, Y., Nozawa, Y., Ootoguro, M. & Suzuki, K. Transfer of *Actinomadura spadix* Nonomura and Ohara 1971 to *Actinoallomurus spadix* gen. nov., comb. nov., and description of *Actinoallomurus amamiensis* sp. nov., *Actinoallomurus caesi* sp. nov., *Actinoallomurus coprocola* sp. nov., *Actinoallomurus fulvus* sp. nov., *Actinoallomurus iriomotensis* sp. nov., *Actinoallomurus luridus* sp. nov., *Actinoallomurus purpureus* sp. nov. and *Actinoallomurus yoronensis* sp. nov. *Int. J. Syst. Evol. Microbiol.* **59**, 1867–1874 (2009).
- Gomi, S. et al. The structures of new antifungal antibiotics, benanomicins A and B. *J. Antibiot.* **41**, 1019–1028 (1988).
- Kim, K. K., Kang, J. G., Moon, S. S. & Kang, K. Y. Isolation and identification of antifungal N-butylbenzenesulphonamide produced by *Pseudomonas* sp. AB2. *J. Antibiot.* **53**, 131–136 (2000).
- Dixon, R. A. & Ferreira, D. Genistein. *Phytochemistry* **60**, 205–211 (2002).
- Hazato, T., Naganawa, H., Kumagai, M., Aoyagi, T. & Umezawa, H. beta-Galactosidase-inhibiting new isoflavonoids produced by actinomycetes. *J. Antibiot.* **32**, 217–222 (1979).
- Anyanwutaku, I. O., Zirbes, E. & Rosazza, J. P. N. Isoflavonoids from streptomycetes: origins of genistein, 8-chlorogenistein, and 6,8-dichlorogenistein. *J. Nat. Prod.* **55**, 1498–1504 (1992).
- Kawaguchi, H. et al. Studies on coumermycin, a new antibiotic—Production, isolation and characterization of coumermycin A1. *J. Antibiot.* **8**, 11–25 (1964).
- Janso, J. E. & Carter, G. T. Biosynthetic potential of phylogenetically unique endophytic actinomycetes from tropical plants. *Appl. Environ. Microbiol.* **76**, 4377–4386 (2010).
- Thamchaipenat, A. et al. *Actinoallomurus acaciae* sp. nov., an endophytic actinomycete isolated from *Acacia auriculiformis* A. Cunn. ex Benth. *Int. J. Syst. Evol. Microbiol.* **60**, 554–559 (2010).
- Indananda, C., Thamchaipenat, A., Matsumoto, A., Duangmal, K. & Takahashi, Y. *Actinoallomurus oryzae* sp. nov., an endophytic actinomycete isolated from root of Thai jasmine rice plant. *Int. J. Syst. Evol. Microbiol.* (doi:10.1099/ijs.0.022509-0) (2010).
- Elleuch, L. et al. Bioactive secondary metabolites from a new terrestrial Streptomyces sp. TN262. *Appl. Biochem. Biotechnol.* **162**, 579–593 (2010).
- Zhan, J. Biosynthesis of bacterial aromatic polyketides. *Curr. Top. Med. Chem.* **9**, 1598–1610 (2009).
- Heide, L. The aminocoumarins: biosynthesis and biology. *Nat. Prod. Rep.* **26**, 1241–1250 (2009).
- Donadio, S., Monciardini, P. & Sosio, M. Polyketide synthases and nonribosomal peptide synthetases: the emerging view from bacterial genomes. *Nat. Prod. Rep.* **24**, 1073–1109 (2007).

- 25 Busti, E. et al. Antibiotic producing ability by representatives of a newly discovered lineage of actinomycetes. *Microbiology* **152**, 675–683 (2006).
- 26 Binz, T. M., Maffioli, S. I., Sosio, M., Donadio, S. & Müller, M. Insights into an unusual nonribosomal peptide synthetase biosynthesis: identification and characterization of the GE81112 biosynthetic gene cluster. *J. Biol. Chem.* **285**, 32710–32719 (2010).
- 27 Sosio, M., Stinchi, S., Beltrametti, F., Lazzarini, A. & Donadio, S. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by *Nonomuraea* species. *Chem. Biol.* **10**, 541–549 (2003).
- 28 Mazza, P., Monciardini, P., Cavaletti, L., Sosio, M. & Donadio, S. Diversity of *Actinoplanes* and related genera isolated from an Italian soil. *Microb. Ecol.* **45**, 362–372 (2003).
- 29 Monciardini, P., Sosio, M., Cavaletti, L., Chiocchini, C. & Donadio, S. New primers for the selective amplification of 16S rDNA from different groups of actinomycetes. *FEMS Microbiol. Ecol.* **42**, 419–429 (2002).
- 30 Lazzarini, A., Cavaletti, L., Toppo, G. & Marinelli, F. Rare genera of actinomycetes as potential producers of new antibiotics. *Antonie Van Leeuwenhoek* **79**, 399–405 (2000).